Chimeric antigen receptor gene modified T cells therapy (Qilu Cell Therapy Engineering&Technology)

N/A

Report date: 2025/07/04 20:00:55

Base Information

Drug NameChimeric antigen receptor gene modified T cells therapy (Qilu Cell Therapy Engineering&Technology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulatorsT lymphocyte replacements
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-CellLymphoma, B-CellLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Qilu Cell Treapy Engineering&Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Qilu Cell Treapy Engineering&Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLymphoma, B-CellLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A